Basiliximab

Ferguson R. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994; 8 (3 Pt 2): 328–31

Arias M, Campistol JM, Vincenti F. Evolving treands in induction therapy. Transplant Rev 2009; 23: 94–102

Tang IY, Meier-Kriesche HU, Kaplan B. Immunosuppressive strategies to improve outcomes of kidney transplantation. Semin Nephrol 2007 Jul; 27(4): 377–92

Binder M, Vogtle FN, Michelfelder S, et al. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res 2007 Apr 15; 67(8): 3518–23

Baan CC, VanRiemsdijk-Overbeeke IC, Boelaars-Van Haperen MJAM, et al. Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients. Transpl Immunol 2002; 10(1): 81–7

Haba T, Uchida K, Katayama A, et al. Pharmacokinetics and pharmacodynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: a comparison between Japanese and non-Japanese patients. Transplant Proc 2001 Nov 31; 33(7-8): 3174–5

Kovarik JM, Rawlings E, Sweny P, et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proceedings 1996 Apr; 28(2): 913–4

Sterkers G, Baudouin V, Ansart-Pirenne H, et al. Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients. Transplant Proc 2000 Dec; 32(8): 2757–9

Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002 Jan; 2(1): 48–56

Kovarik JM, Moore R, Wolf P, et al. Screening for basiliximab exposure-response relationships in renal allotransplantation. Clin Transplant 1999 Feb; 13 (1 Pt 1): 32–8

Kovarik JM, Pescovitz MD, Sollinger HW, et al. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin Transplant 2001 Apr; 15(2): 123–30

Strehlau J, Pape L, Offner G, et al. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients [letter]. Lancet 2000 Oct 14; 356(9238): 1327–8

Sifontis NM, Benedetti E, Vasquez EM. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant Proc 2002 Aug; 34: 1730–2

Kovarik JM, Offner G, Broyer M, et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharma-cokinetic-dynamic evaluations. Transplantation 2002 Oct 15; 74(7): 966–71

Kovarik JM, Korn A, Chodoff L. Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients. Transplant Proc 2001 Nov-2001 31; 33(7-8): 3172–3

Lawen JG, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetilcontaining triple therapy in renal transplantation. Transplantation 2003 Jan 15; 75(1): 37–43

Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997 Oct 25; 350(9086): 1193–8

Parrott NR, Hammad AQ, Watson CJ, et al. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine A monotherapy in renal transplant recipients. Transplantation 2005 Feb 15; 79(3): 344–8

Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006 Nov 9; 355(19): 1967–77

Kyllonen LE, Eklund BH, Pesonen EJ, et al. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Transplantation 2007 Jul 15; 84(1): 75–82

Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004 Aug 27; 78(4): 584–90

Tullius SG, Pratschke J, Strobelt V, et al. ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. Transplant Proc 2003 Sep; 35(6): 2100–1

Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003 Mar; 3(3): 306–11

Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008 Feb; 8(2): 307–16

Vitko S, Klinger M, Salmela K, et al. Two corticosteroid-free regimens —tacrolimus monotherapy after basiliximab administration and tacroli-mus/mycophenolate mofetil — in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation 2005 Dec 27; 80(12): 1734–41

Kumar MS, Xiao SG, Fyfe B, et al. Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin Transplant 2005 Feb; 19(1): 61–9

Nematalla AH, Bakr MA, Gheith OA, et al. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study. Exp Clin Transplant 2007 Dec; 5(2): 673–9

Andres A, Marcen R, Valdes F, et al. A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. Clin Transplant 2009 Jan; 23(1): 23–32

Budde K, Bosmans JL, Sennesael J, et al. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. Clin Nephrol 2007 Mar; 67(3): 164–75

Cibrik D, Meier-Kriesche HU, Bresnahan B, et al. Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. Clin Transplant 2007 Mar; 21(2): 192–201

Hernandez D, Miquel R, Porrini E, et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 2007 Sep 27; 84(6): 706–14

Heldal K, Hartmann A, Leivestad T, et al. Clinical outcomes in elderly kidney transplant recipients are related to acute rejection episodes rather than pretransplant comorbidity. Transplantation 2009 Apr 15; 87(7): 1045–51

Offner G, Toenshoff B, Hocker B, et al. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Transplantation 2008 Nov 15; 86(9): 1241–8

Grenda R, Watson A, Vondrak K, et al. A prospective, randomized, multi-center trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 2006 Jul; 6(7): 1666–72

Webb NJ, Prokurat S, Vondrak K, et al. Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data. Pediatr Nephrol 2009 Jan; 24(1): 177–82

Koch M, Becker T, Lueck R, et al. Basiliximab induction therapy in kidney transplantation: benefits for long term allograft function after 10 years? Biologics 2009; 3: 51–6

Sheashaa HA, Bakr MA, Ismail AM, et al. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. J Nephrol 2003; 16: 393–8

Sheashaa HA, Bakr MA, Ismail AM, et al. Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study. Clin Exp Nephrol 2008 Oct; 12(5): 376–81

Sheashaa HA, Bakr MA, Ismail AM, et al. Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study. Am J Nephrol 2005 May; 25(3): 221–5

Adu D, Cockwell P, Ives NJ, et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003 Apr 12; 326(7393): 789–93

Keown PA, Balshaw R, Khorasheh S, et al. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. Biodrugs 2003; 17(4): 271–9

Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77(2): 166–76

Shah MH, Bokhari MZ, Bokhari MT, et al. Safety and efficacy of basiliximab for the prevention of acute rejection in kidney transplant recipients. Transplant Proc 2003 Nov; 35(7): 2737–8

Lee BM, Oh CK, Jin SH, et al. Effect of basiliximab on renal allograft rejection within 1 year after transplantation. Transplant Proc 2006 Sep; 38(7): 2025–8

Jorge S, Guerra J, Silva S, et al. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference? Transplant Proc 2008 Apr; 40(3): 693–6

Goncalves LF, Ribeiro AR, Berdichevski R, et al. Basiliximab improves graft survival in renal transplant recipients with delayed graft function. Transplant Proc 2007 Mar; 39(2): 437–8

Cho WH, Lee HJ, Kim HT, et al. Basiliximab does not reduce the early rejection incidence in high-risk kidney recipients under tacrolimus-based immunosuppression. Transplant Proc 2008 Sep; 40(7): 2234–6

Al Najjar A, Etienne I, Le Pogamp P, et al. Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. Transplant Proc 2006 Sep; 38(7): 2298–9

Pascher A, Ulrich F, Kohler S, et al. ATG versus basiliximab induction therapy in kidney allograft recipients receiving a dual immunosuppressive regimen: six-year results [abstract no. 800]. 22nd International Congress of the Transplantation Society 2008 Aug 14; 86(2 Suppl.): 279

Haririan A, Morawski K, Sillix DH, et al. Induction therapy with basiliximab versus thymoglobulin in African-American kidney transplant recipients. Transplantation 2005 Mar 27; 79(6): 716–21

Willoughby LM, Schnitzler MA, Brennan DC, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. Transplantation 2009 May 27; 87(10): 1520–9

Gavela Martinez E, Sancho Calabuig A, Escudero Quesada V, et al. Induction treatment with low-dose thymoglobulin or basiliximab in renal transplants from older donors. Transplant Proc 2008 Nov; 40(9): 2900–2

Yang SL, Wang D, Wu WZ, et al. Comparison of single bolus ATG and basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen. Transpl Immunol 2008 Jan; 18(3): 281–5

Taber DJ, Weimert NA, Henderson F, et al. Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation. Transplant Proc 2008 Dec; 40(10): 3401–7

Patolla V, Zhong X, Reed GW, et al. Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant 2007; 7: 1832–41

Knight RJ, Kerman RH, Schoenberg L, et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2004 Sep 27; 78(6): 904–10

Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction: long-term results. Am J Transplant 2005 Oct; 5(10): 2539–48

Chowdhury S, Kode RK, Ranganna K, et al. Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3. Transplant Proc 2001 Feb; 33(1-2): 1057–8

Kumar AM, Fa K, Vankawala R, et al. Simulect, calcineurin inhibitor, mycophenolate mofetil, and prednisone is more effective than OKT3, calcineurin inhibitor, hycophendate mofetil, and prednisone in African American kidney recipients in reducing acute rejections and prolonging graft survival. Transplant Proc 2001 Nov; 33(7-8): 3195–6

Teraoka S, Sato S, Sekijima M, et al. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid. Transplant Proc 2005 Mar; 37(2): 791–4

Woodle ES, Vincenti F, Lorber MI, et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under Simulect, tacrolimus and sirolimus. Am J Transplant 2005 Jan; 5(1): 157–66

Kovac D, Kotnik V, Kandus A. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients. Transplant Proc 2005 Dec; 37(10): 4230–4

Tojimbara T, Sato S, Koyama I, et al. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil. Transplant Proc 2005 Mar; 37(2): 895–8

Balbontin F, Kiberd B, Fraser A, et al. Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period. Clin Transplant 2005 Apr; 19(2): 225–9

Miura M, Harada H, Fukuzawa N, et al. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation. Clin Transplant 2005; 19 Suppl. 14: 54–8

Guba M, Rentsch M, Wimmer CD, et al. Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil. Transpl Int 2008 Jul; 21(7): 637–45

Duzova A, Buyan N, Bakkaloglu M, et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. Transplant Proc 2003 Dec; 35(8): 2878–80

Pape L, Strehlau J, Henne T, et al. Single centre experience with basiliximab in paediatric renal transplantation. Nephrol Dial Transplant 2002 Feb; 17(2): 276–80

Ojogho O, Sahney S, Cutler D, et al. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab. Pediatr Transplant 2005 Feb; 9(1): 80–3

Swiatecka-Urban A, Garcia C, Feuerstein D, et al. Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatr Nephrol 2001 Sep; 16(9): 693–6

Clark G, Walsh G, Deshpande P, et al. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Nephrol Dial Transplant 2002 Jul; 17(7): 1304–9

Baron PW, Ojogho ON, Yorgin P, et al. Comparison of outcomes with low-dose anti-thymocyte globulin, basiliximab or no induction therapy in pediatric kidney transplant recipients: a retrospective study. Pediatr Transplant 2008 Feb; 12(1): 32–9

Delucchi A, Valenzuela M, Ferrario M, et al. Early steroid withdrawal in pediatric renal transplant on newer immunosuppressive drugs. Pediatr Transplant 2007 Nov; 11(7): 743–8

Oberholzer J, John E, Lumpaopong A, et al. Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients. Pediatr Transplant 2005 Aug; 9(4): 456–63

Valenzuela M, Delucchi A, Ferrario M, et al. Early steroid withdrawal in pediatric renal transplantation at a single center: preliminary report. Transplant Proc 2008 Nov; 40(9): 3237–40

Montini G, Murer L, Ghio L, et al. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient. Transpl Int 2005 Jan; 18(1): 36–42

McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008 May; 8(5): 984–9

Ramirez CB, Marino IR. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther 2007 Jan; 7(1): 137–48

National Institute for Clinical Excellence. Immunosuppressive therapy for renal transplantation in adults [online]. Available from URL:http://www.nice.org.uk/nicemedia/pdf/TA085guidance.pdf[Accessed 2009 Oct 12]

Webster AC, Playford EG, Higgins GY, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2009; (3): CD003897

Knoll G. Trends in kidney transplantation over the past decade. Drugs 2006; 68 Suppl. 1: 3–10

Matas AJ. Minimization of steroids in kidney transplantation. Transpl Int 2009; 22: 38–48

Webster AC, Lee VWS, Chapman JR, et al. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006; (2): CD004290

Flechner SM. Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 2009 Apr; 87(8 Suppl.): 1–6

Sarwal MM. Out with the old, in with the new: immunosuppression minimization in children. Curr Opin Organ Transplant 2008; 13: 513–21

Lorber MI, Fastenau J, Wilson D, et al. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. Clin Transplant 2000 Oct; 14(5): 479–85

Walters SJ, Whitfield M, Akehurst RL, et al. Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients. Transplant Proc 2001 Nov 31; 33(7-8): 3187–91

Chilcott JB, Holmes MW, Walters S, et al. The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation. Transpl Int 2002 Oct; 15(9–10): 486–93

Morton RL, Howard K, Webster AC, et al. The cost-effectiveness of induction immunosuppression in kidney transplantation. Nephrol Dial Transplant 2009 Jul; 24(7): 2258–69

Emparan C, Wolters H, Laukotte M, et al. The cost-effectiveness of basiliximab induction in ‘old-to-old’ kidney transplant programs: Bayesian estimation, simulation, and uncertainty analysis. Transplant Proc 2005 Jun; 37(5): 2069–71

Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with bela-tacept in renal transplantation. N Engl J Med 2005 Aug; 353(8): 770–81

Wissing KM, Fomegne G, Broeders N, et al. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation 2008 Feb 15; 85(3): 411–6